Generation of a unique, comprehensive and representative Acute Myeloid Leukemia (AML) patient-derived xenograft (PDX) resource.

Randomized Phase II-like preclinical trials in patient-derived xenografts (PDX) provide an attractive option to define the efficacy of drugs that act via cell-intrinsic mechanisms, and to identify biomarkers of response and resistance across genetically diverse subtypes of leukemia. Here, we generated a unique, comprehensive and representative AML PDX resource that reflects the genetic abnormalities that are found in large clinical trials. Overall design: RNA profiles of AML patient samples that successfully engrafted in NSGS and NRGS recipients.